Cathie Wood’s ARK Invest loads on Archer Aviation’s Tempus AI, but for sale Twist Bioscience: This is the main ark deal this Friday – Archer Aviation (NYSE: ACHR), Accolade (NASDAQ: ACCD)

Cathie Wood on Friday, February 28, 2025 Ark Investment Some significant transactions were made. The most prominent of these is buying Archer Aviation Inc Achr,,,,, Recursive pharmaceutical companies rxrx,,,,, tempus ai inc temand Iris Communications Corporation IRDM.

On the other hand, Ark Investment Decision will Twist Bioscience Corp Twst,,,,, Adyen NV Adid,,,,, Accolade Inc ACCDand Precision Science Company exas.

ACHR Trade

Ark Investment purchased a large number of shares Archer Aviation Inc Among its three ETFs. this Ark Innovation ETF Ak 360,583 shares were purchased. Ark Autonomous Technology and Robotics ETF arkq Obtained 54,699 shares, Ark Space Exploration and Innovation ETF arkx 17,322 shares were added.

Based on Friday’s closing price of $8.88, the total value of those deals is about $3.8 million.

RXRX and TEMES

ARK Invest also showed a strong interest in both Recursion Pharmaceuticals Inc. and Tempus AI Inc. ARKInvest previously bought a large number of shares of Tempus AI, although the company fell after reporting mixed results for the fourth quarter.

Ark Investment Ark Genome Revolution ETF arkg 268,467 shares of recursive drugs and 32,467 shares of tempus AI were purchased.

ARK Innovation ETF acquires 384,956 shares of recursive drug and 49,250 shares of tempus AI.

Given that Tempus AI closed at $56.18 and $7.51 for recursive pharmaceuticals, the total value of these transactions was $36.7 million and $6.11 million, respectively.

IRDM, TWST, Adyey, ACCD and EXAS transactions

ARK Invest’s ARK Innovation ETF purchased 73,659 shares of Iridium Communications Inc and sold 65,290 shares of Twist Bioscience Corp.

Ark Next Generation Internet ETF sells a small stake in Adyen NV (52).

Ark Genome Revolution ETF sold a small number of 80,270 shares of Exact Sciences Corp and Accolade Inc stocks (232).

Read the next article:

Disclaimer: The content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Pictures through Ark Invest